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Background: Liver fibrosis risk is a heritable trait, the outcome of which is the net deposition of extracellular
matrix by hepatic stellate cell-derived myofibroblasts. Whereas nucleotide sequence variations have been
extensively studied in liver fibrosis, the role of copy number variations (CNV) in which genes exist in abnor-
mal numbers of copies (mostly due to duplication or deletion) has had limited exploration.
Methods: The impact of the XPO4 CNV on histological liver damage was examined in a cohort comprised 646
Caucasian patients with biopsy-proven MAFLD and 170 healthy controls. XPO4 expression was modulated
and function was examined in human and animal models.
Findings: Here we demonstrate in a cohort of 816 subjects, 646 with biopsy-proven metabolic associated liver
disease (MAFLD) and 170 controls, that duplication in the exportin 4 (XPO4) CNV is associated with the
severity of liver fibrosis. Functionally, this occurs via reduced expression of hepatic XPO4 that maintains sus-
tained activation of SMAD3/SMAD4 and promotes TGF-b1-mediated HSC activation and fibrosis. This effect
was mediated through termination of nuclear SMAD3 signalling. XPO4 demonstrated preferential binding to
SMAD3 compared to other SMADs and led to reduced SMAD3-mediated responses as shown by attenuation
of TGFb1 induced SMAD transcriptional activity, reductions in the recruitment of SMAD3 to target gene pro-
moters following TGF-b1, as well as attenuation of SMAD3 phosphorylation and disturbed SMAD3/SMAD4
complex formation.
Interpretation: We conclude that a CNV in XPO4 is a critical mediator of fibrosis severity and can be exploited
as a therapeutic target for liver fibrosis.
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Research in context
Evidence before this study
Fibrosis is a highly heritable and polygenic trait; if persistent, it
leads to tissue scarring, organ failure, and eventually, death.
The role CNVs, a more recently appreciated class of large-scale
germline variants on gene function and liver fibrosis remains
under-characterized.
Added value of this study
We examined the relationship between CNV in exportin 4
(XPO4) (13q12.11) with liver damage in MAFLD in a large
cohort of patients of Caucasian ethnicity and delineated its
effector mechanism. We demonstrated that duplication in the
XPO4 CNV is associated with the severity of liver fibrosis. Func-
tionally, this occurs via reduced expression of hepatic XPO4
that maintains sustained activation of SMAD3/SMAD4 and pro-
motes TGF-b1-mediated hepatic stellate cell activation and
fibrosis. This effect was mediated through termination of
nuclear SMAD3 signalling and disturbed SMAD3/SMAD4 com-
plex formation.
Implications of all the available evidence
Our findings suggest that the CNV in XPO4 gene is a genetic risk
marker for the severity of liver fibrosis in MAFLD and may be a
biomarker for risk. Moreover, XPO4 has anti-fibrotic activity via
regulation of TGF-b/SMAD3 signalling suggesting that targeting
this gene has therapeutic potential.
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Fibrosis is a highly heritable and polygenic trait characterized by
the net deposition of extracellular matrix (ECM) in and around
injured tissues; if persistent, fibrosis leads to tissue scarring, organ
failure, and eventually, death [1,2]. Fibrotic diseases including chronic
liver lung and kidney disease and heart failure contribute to »45% of
mortality in affluent countries [3,4] and thus is a substantial burden
on health systems. Limited therapeutic options are currently avail-
able that are directed specifically at the fibrosis process. Thus, a better
understanding of the molecular basis controlling the fibrosis
response is required to facilitate the development of novel therapies.
The advent of genomics generated much interest as a pathway
that could lead to novel drug discovery [5,6]. Several analyses of
pharmaceutical pipelines have suggested that drugs for targets in
which a genetic link to disease is evident has nearly double the likeli-
hood of successful clinical development with improved cost-effec-
tiveness, compared to those not having such a link [7,8].
Out of all the classes of genetic variation that include single nucle-
otide polymorphisms (SNPs), insertions-deletions (inDels) and copy
number variation (CNV), SNPs have occupied a preeminent position
among studied human genetic variations [9]. Genome-wide associa-
tion studies (GWAS) and large candidate gene studies have identified
several SNPs that contribute to an increased likelihood of fibrosis risk
and progression [10-14]. However, these SNPs only explain a propor-
tion of the known disease heritability, reflecting the existence of
‘missing heritability’ [10,15]. Thus, other types of genetic variation
likely exist to explain this missing heritability.
The role CNVs, a more recently appreciated class of large-scale
germline variants on gene function and liver fibrosis remains under-
characterized. CNVs due to duplication or deletion of a sequence is a
form of structural variation defined as changes in the number of DNAcopies (in comparison to the reference) of >1kb; CNVs cover as
much as » 5%-25% of the human genome. Functionally, CNVs com-
prise »17.7% of the detected variations in gene expression [16] and
they do so by altering gene dosage or disrupting the sequences of
genes within partially overlapped regions [17,18] so can exert a pro-
found effect on the risk for disease [1921].
A genome-wide CNV association study in a small cohort of Malay-
sian subjects identified a CNV in exportin 4 (XPO4) to be correlated
with the progression of metabolic (dysfunction) associated fatty liver
disease (MAFLD) [22]. XPO4 maps to chromosome 13q and belongs
to the importin b family which acts as a bidirectional nuclear trans-
port receptor. Decreased XPO4 expression has been shown to associ-
ate with hepatocellular carcinoma [23,24]. Not surprisingly, similar
to SNPs, CNVs exhibit substantial variability in both frequency and
effect size across ethnicities [25,26]. Thus, it is crucial to investigate
whether the effect of this CNV can be replicated to other populations
and if so, to understand the underlying functional mechanism of
action.
In this work, we investigated the role of the CNV in XPO4
(13q12.11) with liver damage in MAFLD in a large cohort of patients
of Caucasian ethnicity and delineated its effector mechanism.
2. Methods
2.1. Patient cohort
The study comprised 646 Caucasian patients with biopsy-proven
MAFLD who had blood samples available for genetic analyses and
representative of their wider populations. In addition, 170 healthy
controls were recruited. Subjects with evidence of secondary causes
of steatosis or alternative diagnoses were excluded including alcohol
abuse (men, >30 g/day; women, >20 g/day), total parenteral nutri-
tion, chronic viral hepatitis (hepatitis B and hepatitis C), autoimmune
liver diseases, hereditary hemochromatosis, a1-antitrypsin defi-
ciency, Wilson’s disease and drug-induced liver injury. The healthy
control group was enrolled from Westmead hospital, Sydney. They
reported no history of chronic liver disease.
2.2. Ethics
Ethics approvals from all participating sites were obtained from
their corresponding Human Research Ethics Committees: The Sydney
West Area Health Service, the University of Sydney, Human Research
Ethics Committee (HREC/17/WMEAD/433), Australia; the Sir Charles
Gairdner Hospital Human Research Ethics Committee, WA, Australia;
Ethical Committee of the Citta della Salute e della Scienza University
Hospital, Torino, Italy; the Ethics committee of the Catholic Univer-
sity of the Sacred Heart, Rome, Italy (Fondazione Policlinico Gemelli
IRCCS: ID 2576); Ethics Committee of Valme University Hospital, Sev-
ille; the Clinical Research Ethics Committee of the La Princesa Univer-
sity Hospital (PI-228/07); Ethics Committee name of the CEIC-
Cantabria, Santander, Spain; and the Ethics Committee of the Hospital
Clinico Universitario de Valladolid, Spain (F0-P07-10). Written
informed consent for genetic testing was obtained from all partici-
pants.
All animal procedures were approved by the Western Sydney
Local Health District Animal Ethics Committee and were conducted
in accordance with the Animal Experimentation guidelines of the
National Health and Medical Research Council (NHMRC) of Australia.
2.3. Clinical and laboratory assessment
Demographic and clinical data were obtained including age, gen-
der, ethnicity, height and weight. Body mass index (BMI) was calcu-
lated as weight divided by the square of the height (kg/m2). Diabetes
was defined as fasting blood glucose  7.0 mmol/L, previous
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sis model assessment (HOMA-IR) was calculated as: (fasting serum
insulin [mU/mL] £ fasting serum glucose [mmol/L])/22.5 [27]. At the
time of liver biopsy, a fasting blood sample was obtained and routine
biochemical tests were performed. Additional blood samples were
drawn and frozen at 80°C for future research.
2.4. Determination of XPO4 CNV
The XPO4 13q12.11 CNV was genotyped using TaqMan CNV real-
time, quantitative PCR assays (Assay Hs03857719_cn). Reactions
were run at least as duplicates with PCR cycling conditions as follows:
1 PCR cycle at 95°C for 10 min, followed by 40 cycles at 95°C for 15
sec and 60°C for 1 min. Negative controls were introduced for every
run to ensure genotyping quality. CN was assigned from the raw Cq
values using CopyCallerTM software (version 2.0; Applied Biosys-
tems). This software provides extensive diagnostics for the validity of
the results and employs a clustering algorithm and assigns the cluster
with the most samples as CN= 2.
2.5. Liver Histopathology
Liver biopsies were scored by an expert liver pathologist in each
participating centre unaware of clinical or genetic data. Histological
scoring was based on the system proposed by Kleiner et al. [28] Stea-
tosis was graded from 0 to 3, lobular inflammation from 0 to 3 and
hepatocellular ballooning from 0 to 2. Fibrosis was staged from 0 to 4
with 4 representing cirrhosis. The activity score (NAS) was calculated
to quantify disease activity [28]. All biopsies were of appropriate size
and included enough portal tracts for pathological grading and stag-
ing of histological features. The inter-observer agreement between
pathologists was studied previously and was excellent for steatosis
(k = 0.85) and good for fibrosis (k =0.78) [29].
2.6. Animal experimentation protocols
Three different models of murine liver fibrosis were employed.
Bile duct ligation: C57BL/6 male mice (68 weeks) were subject to
bile duct ligation (BDL) or Sham for 2 weeks to induce fibrosis as
described previously [30]. Carbon tetrachloride (CCl4)-induced fibro-
sis: male C57BL/6 mice were injected intraperitoneally with CCl4
(1ml kg1 body weight) twice a week for 4 weeks to induce liver
fibrosis. Control mice received an equivalent volume of olive oil.
Methionine and choline-deficient (MCD) diet: experimental steato-
hepatitis was induced by administration of a methionine and cho-
line-deficient (MCD) diet [31]. Male C57BL/6 mice were fed either the
MCD diet or a control diet supplemented with methionine and cho-
line as previously described [32]. Mice had ad libitum access to food
and water. These experiments were conducted in 6-8 mice per group
to detect a difference of 1.5 s.d. in the steatohepatitis Clinical
Research Network (CRN) score. Finally, on completing each experi-
ment, mice were sacrificed. They were weighed and euthanised with
ketamine (100 mg/kg body weight) and xylazine (20 mg/kg body
weight) in normal saline through an intraperitoneal injection. The
mice were assessed for adequacy of anaesthetic by loss of pain
reflexes.
2.7. Cell culture
LX2 cells and JS-1, immortalized human and mouse HSC lines
respectively were cultured with in modified Eagle's medium (Life
Technologies) supplemented with 10% nonheatinactivated fetal
bovine serum and 1% penicillin/streptomycin solution (EuroClone).
Mycoplasma testing and STR profiling of cell lines are done routinely.
Primary human HSCs (ScienCell) were seeded on uncoated plastic
dishes and cultivated with Iscove's modified medium (Dulbecco'smedium; EuroClone, Italy) supplemented with 20% fetal bovine
serum, 1% glutamine 200 mM, sodium pyruvate 100 mM, nonessen-
tial amino acid solution 100 £, and an antibiotic antimycotic solution
100 £ (Gibco Life Technologies, Carlsbad, CA). Primary HSCs between
passages 1 and 8 were used for this study.2.8. XPO4 silencing
Transfection was performed with Lipofectamine RNAiMAX (Invi-
trogen) according to the manufacturer's instructions using 50 -
75 nM of specific Silencer siRNA (Supplementary table 1) or Silencer
Select negative Control for 24 hours, then treated with or without
TGF-b1 (2.5 ug/ml) and harvested after 48 hours. The efficiency of
transfection was evaluated by realtime PCR and western blot.2.9. XPO4 overexpression
Transfection was performed with FuGENE HD (Promega) accord-
ing to the manufacturer's instructions using Human XPO4
(NM_022459.4) DYK tagged ORF clone (Genscript CAT# OHU03871D)
and Xpo4 (NM_020506) Mouse Myc-DDK-tagged ORF Clone (Origene
CAT#: MR220257) or suitable empty vector for 24 hours and then
treated with or without TGF-b1 (2.55.0 ug/ml) and harvested after
48hours later. The efficiency of transfection was evaluated by real-
time PCR and western blot.2.10. Realtime PCR analysis
RNA was isolated from primary HSCs, LX2 cells, JS-1 cells, and
from liver tissues from mice and human liver biopsies by RNeasy
(Qiagen) according to the manufacturer's instructions. 1000 ng of
total RNA was reverse-transcribed into cDNA using qScript cDNA
SuperMix (Quantabio, cat no 95048-500). Three microliters of diluted
complementary DNA were loaded together with SYBR Select Master
Mix on a 96well plate for realtime PCR analysis (Applied Biosys-
tems, Thermo Fisher Scientific). Taqman Probes and Forward and
reverse primers for each gene of interest were specifically designed
and used at 10 pmol/mL; GAPDH was used as the house-keeping
gene. Primer sequences are provided in (supplementary table 2).2.11. Western Blot
Whole cell extracts were fractionated by SDS-PAGE and trans-
ferred to a polyvinylidene difluoride (PVDF) membrane using a trans-
fer apparatus according to the manufacturer’s protocol (Bio-Rad).
Following transfer, membranes were blocked with 5% non-fat milk in
TBST (50 mM Tris, pH 7.4, 150 mM NaCl, 0.05% Tween -20) for 1 hour
at room temperature. Membranes were washed twice with TBST and
incubated with primary antibodies (Supplementary table 3) diluted
in 5% skim milk/TBST, overnight at 4°C. Following incubation, mem-
branes were washed three times for 10 min with TBST and incubated
with secondary antibodies, diluted in 5% skim milk/TBST, for 1 hour
in dark. Blots were washed with TBST three times and developed
with SuperSignal West Pico PLUS Chemiluminescent and SuperSignal
West Femto Maximum Sensitivity Substrates (Life Technologies, Aus-
tralia) according to the manufacturer’s protocol. Membranes were
scanned using ChemiDoc Touch Imaging system (Bio-Rad).2.12. Immunohistochemistry
Slides of human and mouse liver were stained using the BOND RX
Fully Automated Research Stainer (Leica Biosystems) using the Bond
Polymer Refine Detection method (DS9800 Leica).
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Cells were rinsed twice with PBS, fixed with 4% buffered parafor-
maldehyde and permeabilized with 0.5% Triton X-100 for 15 minutes.
Cells were then incubated with the primary antibody overnight at 4°C
and then with the secondary antibody conjugated to rhodamine or
FITC (Molecular Probes) for 1 hour at room temperature. Cells were
examined using a deconvolutional microscope (Zeiss).
2.14. Cell proliferation
Using the Biotrak cell proliferation ELISA system (Amersham, Lit-
tle Chalfont, UK), DNA synthesis was measured by incorporation of
the pyrimidine analogue bromodeoxyuridine (BrdU) into the DNA of
proliferating cells. LX2 cells were cultured in 96 well plates for
24 hours, then further transfected with XPO4 plasmid or siRNA or
their appropriate control in the presence or absence of TGF-b1 for
24 hours. Cells were then labelled with 10 mM BrdU for 24 hours.
After removing the culture medium, cells were fixed and the incorpo-
rated BrdU detected by the subsequent substrate reaction according
to the manufacturer’s protocol.
2.15. Proximity ligation assay
LX-2 cells cultured in Nunc Lab-Tek II chamber slides (Thermo
Fisher Scientific) were treated for 2h with or without 2.5ng/ml TGFb.
Cells were washed 3 times with PBS, fixed with 4% PFA for 20 min on
ice, permeabilized with 0.1% triton, blocked for 1h at 37 degrees
(humidity chamber) using Duolink Blocking Solution (Sigma-
Aldrich), and incubated with both SMAD3 (Thermo Fisher Scientific,
MA5-15663, mouse monoclonal antibody, diluted 1:500) and XP04
(Abcam, ab222384, rabbit polyclonal antibody, 1mg/ml) specific anti-
bodies overnight at 4°C. Both antibodies were diluted using the Duo-
link Antibody Diluent (Sigma-Aldrich). The Duolink proximity
ligation assay (Sigma-Aldrich) was performed to identify SMAD3 and
XPO$4 interactions. PLA probes preparation, ligation, amplification,
final wash step and preparation for imaging was done according to
the manufacturer’s instructions. Cells were visualized using the
Olympus FV1000 confocal microscope and signals were identified
and counted. For each treatment § TGFb, ten representative pic-
tures/condition were analysed.
2.16. Surface Plasmon Resonance Assay
Various concentrations of proteins dissolved in water were manu-
ally printed onto the bare gold-coated (thickness 47 nm) PlexArray
Nanocapture Sensor Chip (Plexera Bioscience, Seattle, WA, US) at 40%
humidity. Each concentration was printed in replicate and each spot
contained 0.2 uL of sample solution. The chip was incubated at 80%
humidity at 4°C overnight, then rinsed with 10 x PBST for 10 min, 1 x
PBST for 10 min, and deionized water twice for 10 min. The chip was
then blocked with 5% (w/v) non-fat milk in water overnight, washed
with 10 x PBST for 10 min, 1 x PBST for 10 min, and deionized water
twice for 10 min before being dried under a stream of nitrogen prior
to use. SPRi measurements were performed with PlexAray HT (Plex-
era Bioscience, Seattle, WA, US). Collimated light (660 nm) passes
through the coupling prism, reflects off the SPR-active gold surface,
and is received by the CCD camera. Buffers and samples were injected
by a non-pulsatile piston pump into the 30 uL flowcell that was
mounted on the coupling prism. Each measurement cycle contained
four steps: washing with PBST running buffer at a constant rate of
2 uL/s to obtain a stable baseline, sample injection at 5 uL/s for bind-
ing, surface washing with PBST at 2 uL/s for 300 s, and regeneration
with 0.5% (v/v) H3PO4 at 2 uL/s for 300 s. All measurements were per-
formed at 25°C. The signal changes after binding and washing (in AU)
are recorded as the assay value. Selected protein-grafted regions inthe SPR images were analyzed, and the average reflectivity variations
of the chosen areas were plotted as a function of time. Real-time
binding signals were recorded and analyzed by the Data Analysis
Module (DAM, Plexera Bioscience, Seattle, WA, US). Kinetic analysis
was performed using BIAevaluation 4.1 software (Biacore, Inc.) via
profacgen (NY, USA).
2.17. Luciferase assay
For TGF-b1induced transcriptional reporter assays, LX-2 and JS-
1 cells were transfected with one of SBE-Luc reporters, SBE4-Luc,
ARE-Luc or SBE2-Luc reporter plasmids (Addgene). Transfection effi-
ciency was normalized by cotransfection with the negative control
plasmid. Luciferase activity was measured using a Dual Luciferase
Assay System (BPSbioscience Catalog #: 60683-1) as per the manu-
facturer's instructions.
2.18. ROS measurement
JS-1 cells were transfected with Xpo4 or control vectors for
24 hour and then treated with TGF-b1 or vehicle control for 6 hours.
Intracellular ROS was measured using the redox-sensitive dye
DCFDA/H2DCFDA- cellular ROS Assay Kit (Abcam, ab113851). Fluo-
rescence intensities were estimated by plate reader analysis.
2.19. RNA-seq
2.19.1. RNA-seq library generation
Total RNA was isolated from the JS1 cell line transfected with
Xpo4 (NM_020506) Mouse Myc DDK-tagged ORF Clone (Origene
CAT#: MR220257) or empty vector treated with or without TGF-b1
(5.0 ng/ml) using the RNA mini kit (Qiagen). RNA purity and integrity
were confirmed using an Agilent Bioanalyzer. Sequencing libraries
were prepared from 100500 ng of total RNA using the TrueSeq RNA
sample preparation kit v2 (Illumina). Briefly, mRNA was purified,
fragmented, and used for first- and second-strand cDNA synthesis
followed by adenylation of 30 _ends. Samples were ligated to unique
adaptors and subjected to PCR amplification. Libraries were then vali-
dated using the 2100 BioAnalyzer (Agilent), normalized and pooled
for sequencing. RNA-seq libraries prepared from three biological rep-
licates for each condition were sequenced on the Illumina HiSeq
2000 using barcoded multiplexing and a 100-bp read length.
2.20. High-throughput sequencing and analysis
Image analysis and base calling were done with Illumina CASAVA-
1.8.2. This yielded a median of 29.9M usable reads per sample. . Read
alignment and junction mapping to genome build GRCh38 was
accomplished using STAR version 2.7.2b (Dobin, 2013 #573). Known
splice junctions from mm10 were supplied to the aligner and de novo
junction discovery was also permitted. Differential gene expression
analysis and statistical testing were performed using Cuffdiff2 ver-
sion 2.2.1 (Trapnell, 2013 #572), employing the Ensembl genome
annotation. Transcript expression was calculated as gene-level rela-
tive abundance in fragments per kilobase of exon model per million
mapped fragments and employed correction for transcript abun-
dance bias (Trapnell, 2013 #572). RNA-seq results for genes of inter-
est were also explored visually using the University of California
Santa Cruz (UCSC) Genome Browser. The software tools gene set
enrichment analysis (GSEA) and ingenuity pathway analysis (IPA)
were used for pathway analyses.
2.21. Chromatin Immunoprecipitation (ChIP-qPCR)
JS1 cells were transfected with Xpo4 (NM_020506) Mouse Myc
DDK-tagged ORF Clone (Origene CAT#: MR220257) or empty vector
(
Table 1
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another 24 hours. Cells were then harvested for Chip assay. The
experimental procedure for ChIP was described previously (Barish,
2010 #574). Briefly, after fixation, nuclei were isolated, lysed in buffer
containing 1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.0, and prote-
ase inhibitors, and sheared with a Diagenode Bioruptor to chromatin
fragment sizes of 2001000 base pairs. Chromatin was immunopre-
cipitated with Smad3 antibody (Abcam cat# ab28379). ChIP-qPCR
assays were performed using biological triplicates with primers listed
in supplementary table 4.
2.22. Collagen Assay
JS-1 cells were transfected with Xpo4 (NM_020506) Mouse Myc
DDK-tagged ORF Clone (Origene CAT#: MR220257) or empty vector
for 24 hours and then treated with or without TGF-b1 (5.0 ng/ml) for
another 24 hours then the collagen assay was performed using the
SircolTM Collagen Assay kit following the manufacturer's instructions.
2.23. Statistical methods
Results are expressed as mean § SEM (standard error of the
mean), median and interquartile range or number (percentage) as
appropriate. The Student’s t-test or Analysis of variance (ANOVA) or
non-parametric, i.e. Wilcoxon-Mann-Whitney U-test or Kruskal-
Wallis tests were used to compare quantitative data as appropriate.
x2 and Fisher-exact tests were used for comparison of frequency data
and to evaluate the relationships between groups. All tests were two-
tailed and p values <0.05 were considered significant. Shapiro-Wilk
test was used to test the assumption of normality as appropriate.
Multivariable regression modelling with backward elimination was
undertaken to test independent associations of the XPO4 CNV with
the following steatosis; ballooning, inflammation; and fibrosis using
ordinal regression models for ordinal traits and multiple logistic
regression models were fitted to binary traits incorporating biologi-
cally relevant covariates associated with the risk of liver disease pro-
gression (age, gender, Body Mass Index (BMI), ALT and presence of
type 2 diabetes mellitus (T2DM)). For this analysis, steatosis was
dichotomized as mild (S1) or moderate/severe (S2S3); inflamma-
tion was dichotomized as absent/mild (A0A1) or moderate/severe
(METAVIR score A2A3), and fibrosis as no fibrosis (F0) and fibrosis
(F1F4). Results are expressed as odds ratios and 95% confidence
intervals (CI).
List of siRNAs and negative control used.Characteristics of the patient cohort with MAFLD.
SiRNA name Cat no companyVariables MAFLD cohort (n=646)
SMARTpool: ON-TARGETplus Mouse Xpo4
siRNA
L-062054-01-0010 DharmaconAge (years) 48.4 (38-57)
Male (%) 351 (54.3)ON-TARGETplus Human DNMT1 (1786) siRNA -
SMARTpool,L-004605-00-0005 DharmaconBMI (Kg/m2) 33.3 (29-42)
ALT (IU/L) 55 (34-84)ON-TARGETplus Human DNMT3A (1788) siRNA
- SMARTpoolL-006672-01-0005 DharmaconAST (IU/L) 36 (26-52)
GGT (IU/L) 57 (32-114)ON-TARGETplus Human DNMT3B (1789) siRNA
- SMARTpoolL-006395-00-0005 DharmaconPlatelets (x109/L) 247 (199-298)Human XPO4 4390771 AmbionDiabetics (%) 167 (25.9)ON-TARGETplus Non-targeting Pool D-001810-10-05 DharmaconCholesterol (mmol/L) 4.84 (4.1-5.7)Control#1 siRNA 4390843 AmbionTriglycerides (mmol/L) 1.6 (1.12-2.26)
HDL-C (mmol/L) 1.2 (1-1.51)
LDL-C (mmol/L) 2.8 (2.21-3.51)Primer sequences used for RT-PCR.Blood glucose (mmol/L) 5.5 (4.95-6.58)Primer Name Forward (5’ to 3’) Reverse (5’ to 3’)
HOMA-IR 3.46 (2.22-5.61)
Steatosis grade 2-3 (%) 287 (44.4)Human XPO4 GGC AAA GAC TTA TCT CCT GGT GG CTG TAT CTG CTC CGA ACG CTG T
Human GAPDH CCT GCA CCA CCA ACT GCT TA GGC CAT CCA CAG TCT TCT GAGInflammation 2-3 (%) 188 (29.2)
Human aSMA GAC AAT GGC TCT GGG CTC TGT AA ATG CCA TGT TCT ATC GGG TAC TTFibrosis Stage 2-4 (%) 242 (37.5)
Human Mmp9 GAA CCA ATC TCA CCG ACA GG GCC ACC CGA GTG TAA CCA TA
Human TIMP-1 ACTTCCACAGGTCCCACAAC CACTGTGCATTCCTCACAGCValues are median with interquartile range or fre-
quency and percentage.(continued)Continued)Primer Name Forward (5’ to 3’) Reverse (5’ to 3’)Human CTGF AAT GCT GCG AGG AGT GGGT CGG CTC TAA TCA TAG TTG GGT CT
Mouse XPO4 GGC AGC ATC GAG TCA CCC GAA CAT ACT TTT
Mouse GAPDH CAC CAT CTC CCA GGA GCG CAG CCT TCT CCA TGG TGG TGC AGA
Mouse TGF-b GTGGGGACTTCTTGGCACT GAGTGTCCACGACGGTGAG
Mouse Col1a1 AGGAGAACCAGGTGACGAAG CCCCAGCTTCTCCTTTCTCT
Mouse a-SMA CTCTCTTCCAGCCATCTTTCAT TATAGGTGGTTTCGTGGATGC
Mouse TIMP-1 GCAAAGAGCTTTCTCAAAGAC AGGGATAGATAAACAGGGAAACACT
Mouse MMP-9 GATGCGTGGAGAGTCGAAAT CACCAAACTGGATGACGATGAntibodies used for Western blot.Antibody name Cat no companyAnti-Xpo4 antibody NB100-56495 Novus Biologicals
Anti- a-Smooth Muscle Actin Antibody 14968 Cell Signaling Technology
Anti-beta Actin antibody ab8227 Abcam
Anti-Smad 3 antibody 9513 Cell Signaling Technology
Anti-Smad4 antibody 38454 Cell Signaling Technology
Anti-GAPDH antibody ab8245 AbcamList of primer sequences for Chromatin Immunoprecipitation







m Ccn2/Ctgf_-32B TCACATTCCTCCCCACCTTC2.24. Role of funding source
The funders had no role in study design, data collection, data anal-
yses, interpretation, or writing of report.
3. Results
3.1. Duplication of the XPO4 CNV increases the severity of liver fibrosis
in patients with MAFLD
The baseline clinical features of MAFLD patients are depicted in
Table 1. In this cohort, XPO4 CNVs ranged from 0 to 8 copies per indi-
vidual. 267 (41.3%) were copy number neutral, 52 (8.1%) had dele-
tions, while 327 (50.6%) had duplications. In contrast, in the control
Fig. 1. In MAFLD, the XPO4 CNV is associated with the severity of liver damage in
patients with MAFLD. CNV gain (duplication) compared to non-gain (CNV neutral or
deletion) in XPO4 in a cohort of MAFLD (n=646). p values represent the significance of
a trend in the prevalence of more severe degrees of histological damage according to
different copy number status.
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and 3 (1.8%) had duplications. The very low prevalence of duplica-
tions and deletions in the general population suggested to us a poten-
tial pathogenic role for XPO4 in MAFLD.
Therefore, we investigated the association of XPO4 CNVs with the
spectrum of liver damage related to MAFLD. CNV duplication was
associated with more advanced fibrosis, hepatocellular ballooning,
severe inflammation and with reduced hepatic steatosis (p<0.009,
for all) compared to combined non-duplications (neutral and dele-
tions combined) (Fig. 1). In addition, carriers of the CNV duplication
had higher mean fibrosis (1.44 vs. 1.28, p=0.01), inflammation
(1.26 vs. 0.89, p=0.0001) and hepatocellular ballooning (1.2 vs. 0.76,
p=0.0001) but lower steatosis (1.57 vs. 1.71, p=0.01) compared to
combined non-duplications (neutral and deletions combined) using
the Student’s t-test in all comaprisons. Similar findings were
observed when we compared CNV duplications to both CNV deletions
and neutral status (Supplementary Fig. 1). In multivariable logistic
regression analysis adjusted for age, sex, BMI, ALT and T2DM, CNV
duplication conferred an increased risk for the presence of fibrosis
(OR=1.98; 95% CI: 1.36-2.89, p=0.0001) (Supplementary Table 1). The
results were virtually similar in three other models, one including
HOMA-IR with the above mentioned variables, a second including
AST instead of ALT and a third including AST/ALT ratio instead of ALT.
3.2. XPO4 correlates with liver fibrosis in humans and murine models
To investigate the involvement of XPO4 to fibrosis, we examined
its hepatic expression in control subjects (n=25) and patients with
MAFLD related fibrosis (F1) (n=38). XPO4 mRNA levels were consid-
erably decreased in the livers of patients with fibrosis compared to
that in controls (p<0.0001, using the Student’s t-test) (Fig. 2a). Con-
sistently, immunohistochemistry revealed that XPO4 was decreased
in the liver of patients with MAFLD related fibrosis compared to that
from controls (Fig. 2b). In addition, we observed that copy number
amplification of XPO4 was negatively correlated with its mRNA
expression; expression levels of XPO4 decreased when comparing
those with deletions to those without (P<0.05, using the ANOVAtest) (Fig. 2c), indicating that copy number gain contributes to down-
regulation of XPO4.
We proceeded to determine whether xpo4 is similarly downregu-
lated in experimental liver injury models. Compared with controls,
liver sections of mice treated with carbon tetrachloride (CCL4) for 4
weeks showed increased collagen deposition indicated by hematoxy-
lin and eosin (H&E), Sirius red and trichrome staining (Fig. 2d). Con-
sistent with the human data, xpo4 mRNA levels by real time
quantitative PCR (RT-qPCR) and intensity of staining by IHC in liver
sections was less than that in control mice (Fig. 2d,e). To ensure that
the changes were not model-specific, the observations were repli-
cated in two other models of liver injury, namely, bile duct ligation
(BDL) for 2 weeks and in mice fed a methionine and choli-
nedeficient (MCD) diet for 6 weeks. The latter model is more repre-
sentative of fibrosis associated with steatohepatitis (Fig. 2d,e).
3.3. XPO4 is highly expressed in hepatic stellate cells
Next, to dissect the function of XPO4 during liver fibrosis, we ana-
lysed its expression in different cell types of the liver, namely hepato-
cytes, hepatic stellate cells (HSC), and hepatic sinusoidal endothelial
cells (HSEC). The highest expression level of XPO4 was found in HSCs
followed by HSEC; expression levels were low in hepatocytes (Sup-
plementary Fig. 2a).
HSCs activate and differentiate into myofibroblasts that produce
extracellular matrix during the process of fibrosis in vivo, and sponta-
neously activate under culture conditions [33]. Consistent with a role
in fibrosis, XPO4 mRNA decreased from the first to the fourth passage
(P < 0.01), opposite to the increasing levels of the profibrogenic cyto-
kine connective tissue growth factor (CTGF) (P < 0.05) (Supplemen-
tary Fig. 2b,c). We tested whether transforming growth factor beta
(TGF-b), a major HSC activator and a potent fibrosis promoting stim-
ulus might regulate the expression of XPO4. In line with the downre-
gulation of XPO4 in HSCs during hepatic fibrosis, stimulation of a
human HSC cell line (LX-2), a mouse HSC cell line (JS-1), and primary
HSCs with recombinant TGFb1 resulted in a significant decrease in
the expression of XPO4 mRNA and protein levels that correlating
with an increase in a-Smooth muscle actin (a-SMA) and CTGF
expression in these cells (Supplementary Fig. 2d-f).
In total, these data indicate that XPO4 has high expression in
HSCs, is downregulated during liver fibrosis and during culture acti-
vation of hepatic stellate cells, raising the possibility that it could be
involved in the process of HSC activation in fibrosis.
3.4. XPO4 regulates the phenotype of hepatic stellate cells
To further explore the role of XPO4 in fibrosis and HSC activation
in a systematic unbiased manner, we overexpressed Xpo4 in JS-1
cells and undertook RNA-Seq analysis. As shown in Supplementary
Fig.s 3a and b, transfection of an XPO4 plasmid into JS-1 cells for
48hours led to increased XPO4 mRNA and protein expression com-
pared with the negative control. Ingenuity pathways analysis (IPA,
Ingenuity systems, Inc., Redwood City, CA) analysis revealed that
hepatic fibrosis/hepatic stellate cell activation was one of the top sig-
nificant overlapping pathways to be altered in XPO4 overexpressed
cells Fig. 2a. GSEA analysis similarly found significant enrichment in
gene sets associated with extracellular matrix and collagen-related
pathways in the control cells compared to XPO4 overexpressed cells
Fig. 3b. Further, XPO4 overexpression comprehensively suppressed
profibrotic gene expression, both in the absence and presence of
TGFb1 as illustrated in Fig. 3c.
To validate the RNA sequencing data, RT-PCR analysis was used to
quantify changes in mRNA expression of a subset of fibrosis markers.
Xpo4 overexpression led to a dramatic decrease in the expression of
Acta2, Col1a1 and Ctgf in cells treated with or without TGFb1
(Fig. 3d). Conversely, knockdown using Xpo4 siRNA decreased Xpo4
Fig. 2. XPO4 expression is decreased with fibrosis in humans and in multiple fibrosis models in mice. a) Relative hepatic mRNA levels of XPO4 measured by RT-PCR and normalized
to GAPDH as internal control in MAFLD patients with fibrosis (n=38) and in controls (n=28). b) Immunohistochemistry (IHC) staining for XPO4 in liver sections from representative
MAFLD patients with fibrosis and in controls with normal liver histology. c) Relative hepatic mRNA levels of XPO4 by XPO4 CNV status (duplication, neutral or deletion). d) Hema-
toxylineosin (H&E), Sirius red and G€om€ori trichrome staining and IHC for Xpo4 in liver sections from representative mice treated with vehicle or carbon tetrachloride (CCl4) (1ml
kg1 body weight, i.p., twice a week, for 4 weeks), bile duct ligation (BDL) or Sham operation, or maintained on a methionine and cholinedeficient (MCD) or control diet (CD) for 6
weeks (as a model of metabolic (dysfunction) associated steatohepatitis related fibrosis. e) Relative hepatic mRNA levels of Xpo4 measured by RT-PCR and normalized to Gapdh as
internal control in mice from the CCl4, BDL or MCD models. Results are expressed as mean§ SEM; statistical significance of the differences between groups was calculated using
the unpaired two-sample Student’s t-test or ANOVA test. *P<0.05, ** P<0.01, *** P<0.001.
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of the same genes (Fig. 3e). Furthermore, increased Xpo4 expression
led to decreased collagen levels measured by a collagen quantitative
assay (Fig. 3f), the a-SMA protein level by immunofluorescence
(Fig. 3,h) and reactive oxygen species (ROS) level measured by fluo-
rescence intensity (Fig. 3i). Similar findings were obtained in human
LX-2 cells (Supplementary Fig. 4) suggesting that the effect of XPO4 is
conserved across species.During fibrosis resolution, increased activity of extracellular
matrix (ECM)-degrading enzymes such as matrix metalloprotei-
nases (MMPs) play a pivotal role [34]. XPO4 overexpression
increased MMP-9, while its inhibition decreased levels in both
LX-2 and JS-1 cells (Fig. 3 and Supplementary Fig. 4). Modulation
of XPO4 expression on HSCs did not affect cell proliferation at
basal levels and in response to TGFb1 in both cell lines (Supple-
mentary Fig. 5).
Fig. 3. Inhibition of HSC activation and the modulation of TGFb1 effects by XPO4. a) Ingenuity pathways analysis (IPA, Ingenuity systems, Inc., Redwood City, CA) revealed that
hepatic fibrosis/hepatic stellate cell activation was one of the top significant overlapping pathway altered in XPO4 overexpressed cells compared to control. b) GSEA analysis simi-
larly found significant enrichment in gene sets associated with extracellular matrix and collagen-related pathways in control cells compared to XPO4 overexpressed cells c) Heat
map of fold change of genes involved in fibrosis in murine JS-1 HSCs in Xpo4 overexpressed cells compared to control for 24 hours followed by TGFb1 (2.5 ng/ml) treatment or vehi-
cle control for 24 h using log2-transformed mRNA-Seq expression data, n = 4 per group. d) Acta2, Col1a1, Ctgf, Tgfb1, Mmp9 and Timp1 qRT-PCR analysis in murine HSCs transfected
with control or Xpo4 vector for 24 hours followed by TGFb1 (2.5 ng/ml) or vehicle control treatment for 24 h. e) RT-PCR analysis for the same panel of genes in murine HSCs trans-
fected with control or Xpo4 siRNA for 24 hours followed by TGFb1 (2.5 ng/ml) or vehicle control treatment for 24 h. f) COL1A1 level as measured by SircolTM Collagen Assay, g)
Acta2 expression as assessed by immunofluorescence and h) measured fluorescence intensity and i) ROS generation as measured by fluorescence intensity was significantly reduced
in Xpo4-vector-transfected JS-1 cells treated with or without TGFb1 (2.5 ng/mL for 24 h) compared to control. Results are expressed as mean§ SEM of at least three independent
experiments performed in triplicate; statistical significance of the differences between groups was calculated using the unpaired two-sample Student’s t-test or ANOVA test.
*P<0.05, ** P<0.01, *** P<0.001.
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Fig. 4. XPO4 interaction with SMADs. a-f) Surface plasmon resonance (SPR) sensorgrams for the interaction between XPO4 and SMAD proteins (SMAD1, SMAD2, SMAD3, SMAD4, SMAD5 and
SMAD6) shown as dissociation constant (KD) values. g) The XPO4 interaction with SMAD3 was confirmed using a proximity ligation assay in the presence or absence of TGF-b1. Confocal
microscopy demonstrated enhancement in fluorescent signals (red fluorescent spots), indicative of an XPO4:SMAD3 interaction (within 40nm) with and without TGF-b1. No signal was
observed in the negative control assay containing the 2 antibodies with one probe only. h) Proximity ligation signals were quantified and are presented as signal per nuclei. Data are representa-
tive of two independent experiments. i) Schematic illustration of SMAD3 deletion mutants. The numbers indicate the amino acid positions. j) Surface plasmon resonance (SPR) sensorgrams of
the interaction between XPO4 and SMAD3 deletion mutants shown as dissociation constant (KD) values. Results are expressed as mean§ SEM; the p-value was calculated using the unpaired
two-sample Student’s t-test. *P<0.05, ** P<0.01, *** P<0.001. KD value:>106: low;108-106: medium; 109-108: high binding.
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To understand how XPO4 affects TGFb1 signalling during HSC
activation we proceeded to identify XPO4 interaction with different
SMADs, the major mediators of TGF-b signalling [35]. It has been
reported that XPO4 interacts with SMAD3 [36], but whether this
effect applies to all cell types responding to TGF-b, including HSCs is
unknown. Further, it is not known whether XPO4 is a non-specific
exporter for all SMADs or whether it interacts selectively with
SMAD3. To this end, we measured the binding affinity of XPO4 to
SMADs 1-6 using surface plasmon resonance (SPR) spectroscopy
where XPO4 is immobilized on the sensor chip. A higher binding profile
was observed with SMAD3, with a binding constant (KD) of 4.88 £ 109
M, with medium binding demonstrated for SMAD1, SMAD2 and SMAD4
and low binding for SMAD5 and SMAD6 (Fig. 4a-f).
To confirm the XPO4/SMAD3 interaction in HSCs, we performed a
Duolink proximity ligation assay (PLA) with XPO4 and SMAD3 spe-
cific antibodies. PLA generates fluorescence when 2 proteins are
within 40 nm [37]. As shown by the interaction signals per cell, this
confirmed strong binding of XPO4 with SMAD3 at baseline that was
reduced after TGFb1 stimulation, (Fig. 4g,h). Negative control PLA
experiments omitting either XPO4 or SMAD3 probe demonstrated no
signal amplification, confirming the validity of the assay. Moreover, using
the UCSC genome browser, SMAD3 binds to the XPO4 gene principally at
intronic sequences in the 5’ region (Supplementary Fig. 6).
We next determined the minimal region crucial for the XPO4-
SMAD3 interaction. A series of N-terminal and C-terminaltrun-
cated SMAD3 mutants were generated (Fig. 4i) and surface plasmon
resonance was undertaken to map the domain of SMAD3 that associ-
ated with XPO4 with high affinity and specificity. This revealed inter-
action between SMAD3 and XPO4 through cooperative binding to
both the MH1 and MH2 domains (Fig. 4j).3.6. XPO4 regulates TGF-b/SMAD3-induced transcriptional activity
We next investigated how XPO4 modulates TGF-b1-SMAD signal-
ling in HSC using various SMAD-dependent gene reporters. As
expected, increased expression of XPO4 caused a decrease in basal
and TGFb1-dependent transcription from the SMAD-binding element
(SBE)-Luc reporter in both JS-1 and LX-2 cells (Fig. 5a,b), with an
opposite effect using siRNA (Fig. 5c,d). To specify the effect on differ-
ent SMADs, we tested the effect of XPO4 on SBE4-Luc, a SMAD3-spe-
cific luciferase reporter construct, ARE-Luc, a TGF-b1responsive but
SMAD2-specific luciferase reporter and SBE2-Luc, a SMAD4-specific
luciferase reporter. Increased XPO4 in LX-2 and JS-1 cells resulted in
a decrease in the activity of SBE4-Luc, but not the activity of ARE-Luc
or SBE2-Luc (Fig. 5e,f). In addition, using our RNA-Seq on JS-1 cells,
we found that Xpo4 overexpression decreased Smad3 expression,
but not other Smads from 1-6 (Fig. 5g).
Finally, chromatin immunoprecipitation (ChIP) studies demon-
strated that Smad3 binding to the promoters of pro-fibrotic genes
such as Col1a1, Acta2, Ctgf and Timp2 in response to TGFb1 is signifi-
cantly reduced by Xpo4 overexpression (Fig. 5-k), further confirming
a direct role of XPO4 in modulating profibrotic gene expression via a
preferential impact on TGFb1/SMAD3 signalling.3.7. XPO4 decreases SMAD3 phosphorylation level and nuclear retention
Phosphorylation of SMADs by the activated TGFb1 receptor com-
plex is an essential event in the initiation of TGFb1 signal transduc-
tion [35]. Thus, we monitored the status of SMAD3 phosphorylation
as well as of SMAD4 in response to TGFb1 stimulation of HSCs. As
shown in Fig. 6a, while TGFb1 induced robust SMAD3 phosphoryla-
tion in control cells, increased XPO4 reduced the phosphorylation
level of SMAD3 in response to TGFb1, with no effect on SMAD4.Nuclear localization of SMAD3 and its direct binding to target
gene promoters is required for downstream TGFb1 signalling [38]. To
characterise the molecular mechanism of XPO4 regulation of SMAD3
activity in HSCs, we determined whether XPO4 might modify the
nuclear translocation of SMAD3. To this end, the location of SMAD3
in the nuclear and cytoplasmic fractions of TGFb1 or vehicle treated
HSCs were determined using immunofluorescence staining. As
expected, TGFb1 treatment robustly increased the nuclear localiza-
tion of SMAD3, while XPO4 overexpression decreased the level of
nuclear SMAD3 and concomitantly was associated with increased
levels of cytoplasmic SMAD3, compared to control cells (Fig. 6b, c).
3.8. XPO4 disturbs the SMAD3/SMAD4 complex
Lastly, we tested whether XPO4 limits the binding of SMAD3 to
SMAD4 since the formation of the SMAD3/SMAD4 complex is neces-
sary for the nuclear retention of SMAD3 [38]. As visualized by immu-
nofluorescence, SMAD3 and SMAD4 colocalized in the nucleus when
induced by TGFb1 in LX-2 cells, whereas overexpression of XPO4
reduced this nuclear colocalization (Fig. 6d). This confirmed that
XPO4 plays an essential in limiting the sustained activation of the
SMAD3/SMAD4 complex (Fig. 6e).
4. Discussion
In this work, we found that duplication of CNV 13q12.11 in XPO4
is associated with an increased severity of liver fibrosis in patients
with MAFLD. Mechanistically, this resulted in decreased expression
of hepatic XPO4, which maintains sustained SMAD3/SMAD4 activa-
tion and promotes TGFb1 mediated HSC activation and fibrosis fol-
lowing liver injury.
The modest size of genetic effects detected so far confirms the
multifactorial aetiology of fibrosis and suggests that as with other
complex diseases, additional genetic influences exist that are yet to
be identified [9]. CNVs are a common form of genetic variation play-
ing an important role in the generation of genetic diversity often
influencing gene expression and transcriptional regulation to a
greater extent than the more commonly described single nucleotide
polymorphism (SNPSs) [39-41]. The clinical consequences of a CNV
depend on many factors including ethnic background or environ-
mental factors [42]. Here, in a large cohort of Caucasian patients, we
demonstrated that duplication of a rare and modest size CNV (18 Kb)
in the XPO4 gene conveys an increased risk for severe fibrosis in
patients with MAFLD. Approximately 80% of common CNVs (minor
allele frequency > 5%) have been well-tagged by SNPs [43]. However,
most low-frequency CNVs and multi-allelic CNVs are poorly tagged
by SNP-based GWAS but they could be informative in terms of the
discovery of missing heritability [43]. In our control cohort, » 95% of
individuals had two copies (copy number neutral), while < 2% has a
duplication; in marked contrast the prevalence of duplication in
adults with MAFLD was >50%, supporting a likely functional role. Our
findings are also consistent with the original CNV GWAS in a small
Malaysian cohort (49 patients with MAFLD (39 with steatohepatitis
and 10 with simple steatosis) and 49 matched controls) that found
this CNV exclusively in patients with but not in controls [22]. In a
subsequent study from the same group in a cohort of 249 patients
with MAFLD, the CNV duplication was observed in 34% of the steato-
hepatitis cohort but in 19% of controls [44]. The reasons of this discor-
dance is not clear.
TGF-b is the principal cytokine mediating fibrosis and though
therapies that neutralize TGFb show anti-fibrotic activity, the bene-
fits are compromised by unwanted systemic effects and the differen-
tial contribution of each R-SMAD [45,46]. SMADs are a family of
structurally related intracellular proteins and possess intrinsic nucle-
ocytoplasmic shuttling capacity which enables them to transmit TGF-
b signals from the cell membrane to the nucleus serving as signalling
Fig. 5. XPO4 regulates TGF-b/SMAD3-induced transcriptional activity in HSCs. JS-1 (mouse) and LX-2 (human) HSCs were transfected with a control or XPO4 vector for 24 hours fol-
lowed by TGFb1 (2.5 ng/ml) or vehicle treatment for 24 h. The luciferase activity was measured by a dual luciferase assay for the SMAD-binding element (SBE)-Luc reporter in a) JS-1
cells and b) LX-2-cells. JS-1 and LX-2 cells were transfected with a control or XPO4 siRNA for 24 hours followed by TGFb1 (2.5 ng/ml) or vehicle treatment for 24 h. The luciferase
activity was measured by a dual luciferase assay for the SMAD-binding element (SBE)-Luc reporter in c) JS-1 cells and d) LX-2-cells. JS-1 and LX-2 cells were transfected with a con-
trol or XPO4 vector for 24 hours followed by TGFb1 (2.5 ng/ml) or vehicle treatment for 24 h. The luciferase activity was measured by a dual luciferase assay for the SBE4-Luc, a
SMAD3-specific luciferase reporter construct, ARE-Luc, a TGF-b1responsive but SMAD2-specific luciferase reporter and SBE2-Luc, a SMAD4-specific luciferase reporter in e)JS-1
and f) LX-2 cells. g) Heat map of the SMAD 1-6 genes expression in XPO4 overexpression cells compared to control for 24 hours followed by TGFb1 (2.5 ng/ml) or vehicle treatment
for 24 h. Only Smad3 showed significant alteration wit Xpo4 overexpression at both conditions. JS-1 cells were transfected with a control or XPO4 vector for 24 hours followed by
TGFb1 (2.5 ng/ml) or vehicle treatment for 24 h and ChIP-qPCR was undertaken. Cells were immunoprecipitated with Smad3 antibody and analysed by qPCR using primers flanking
h) Col1a1, i) Acta2, j) Ccn2/Ctgf and k) Timp2. XPO4 overexpression attenuated binding of SMADs to the promoters of these pro-fibrotic genes. Values are mean §SEM for triplicate
samples. Statistical significance was determined by the unpaired two-sample Student’s t-test. P<0.05, ** P<0.01, *** P<0.001.
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Fig. 6. XPO4 decreases SMAD3 phosphorylation and nuclear retention and disturbs the SMAD3/SMAD4 complex in HSCs. a) Immunoblot for SMAD3, p-SMAD3 and SMAD4. XPO4
was overexpressed in LX-2 cells for 48 hours and continuously treated with 2.5 ngml1 TGFb1 for 240min. b) LX-2 cells were transfected with a control or XPO4 vector for 48 hours
followed by TGFb1 (2.5 ng/ml) or vehicle treatment for 1 hour. The cells were stained with an anti-SMAD3 and then by a FITC-conjugated anti-rabbit secondary antibody (green, for
SMAD3); nuclei were visualized with DAPI (blue). Scale bars: 20 mm. c) Intensity of nuclear SMAD3 in cells was quantified using ImageJ software. The percentages of nuclear
SMAD3 shown at the right represents the mean of two independent experiments; error bars indicate the SEM. Scale bars: 20 mm. d) LX-2 cells were transfected with a control or
XPO4 vector for 48 hours followed by TGFb1 (2.5 ng/ml) or vehicle treatment for 1 hour. The cells were stained with an anti-SMAD3 or anti-SMAD4 antibody and then by a rhoda-
mine-conjugated anti-mouse secondary antibody (red, for SMAD4) or a FITC-conjugated anti-rabbit secondary antibody (green, for SMAD3); the nuclei were visualized with DAPI
(blue). Scale bar: 20 mm. Values are mean §SEM for triplicate samples. Statistical significance was determined by the unpaired two-sample Student’s t-test. P<0.05, ** P<0.01, ***
P<0.001. e) Proposed scheme illustrating the effect of XPO4 on TGF-b1-mediated SMAD3 activation in HSCs. XPO4 has preferential interaction with SMAD3 and inhibits TGFb1-
mediated SMAD3 phosphorylation. XPO4 also decreases the nuclear retention of SMAD3 and disturbs the SMAD3/SMAD4 complex in HSCs at baseline and in response to TGFb1.
The inhibition of HSC response to TGFb1 may contribute to the anti-fibrotic effect of XPO4.
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tion and strength of signalling is the continued presence of these
effectors/mediators in the nucleus [47]. In contrast to SMAD3 that
promotes tissue fibrosis, SMAD2 protects against TGFb-mediated
fibrosis [48]. Thus, identifying potential specific regulators of TGFb
signaling might be a more promising approach. XPO4 expression we
demonstrate was decreased with advanced liver fibrosis in humans
and in murine models of fibrosis. From the cohort data, increasing
fibrosis also associated with increasing copies of the XPO4 CNV. Our
studies confirmed the inhibitory effects of XPO4 on HSC activation
through antagonistic effects on TGF-b signalling. This effect was
mediated through termination of nuclear SMAD3 signalling. XPO4
demonstrated preferential binding to SMAD3 compared to other
SMADs and led to reduced SMAD3-mediated responses as shown by
attenuation of TGFb1 induced SMAD transcriptional activity, reduc-
tions in the recruitment of SMAD3 to target gene promoters follow-
ing TGF-b1, as well as attenuation of SMAD3 phosphorylation and
disturb SMAD3/SMAD4 complex formation [38]. Decreased retention
of SMAD3 in the nucleus leads to attenuation of TGF-
b/SMAD3mediated transcriptional activity and target gene expres-
sion (Fig. 6e), while it has no impact on other SMAD family members.
Collectively, these findings suggest that XPO4 might be a novel target
to treat liver fibrosis with potentially less side effects. As TGF-
b/SMAD3 is implicated in the progression of fibrosis in virtually all
liver diseases, it would be interesting to explore the role of XPO4
CNVs in other liver disease in future studies.
The study has some limitations. The detailed characteristics of
subjects in the control cohort were not available. Therefore, their
matching to subjects with MAFLD was not feasible. However, the
main focus of this study was to explore the impact of XPO4 CNV on
the histological severity of MAFLD and to delineate the functional
mechanisms. Second, details of medications for patients with MAFLD
were not available for a large proportion of patients and so we could
not undertake further analyses for their correlation with the XPO4
CNV.
In conclusion, our findings suggest that the CNV in XPO4 gene is a
risk genetic variation for the severity of liver fibrosis in MAFLD and
may be a biomarker for risk. Moreover, XPO4 has anti-fibrotic activity
via regulation of TGF-b/SMAD3 signalling, suggesting the therapeutic
potential of this molecule.Contributors
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